Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Liabilities: 2017-2024

Historic Total Liabilities for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $665.0 million.

  • Arcus Biosciences' Total Liabilities fell 26.80% to $538.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $538.0 million, marking a year-over-year decrease of 26.80%. This contributed to the annual value of $665.0 million for FY2024, which is 5.06% up from last year.
  • Arcus Biosciences' Total Liabilities amounted to $665.0 million in FY2024, which was up 5.06% from $633.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Total Liabilities registered a high of $750.4 million during FY2021, and its lowest value of $270.0 million during FY2020.
  • Its 3-year average for Total Liabilities is $647.0 million, with a median of $643.0 million in 2022.
  • Per our database at Business Quant, Arcus Biosciences' Total Liabilities spiked by 587.55% in 2020 and then dropped by 14.32% in 2022.
  • Over the past 5 years, Arcus Biosciences' Total Liabilities (Yearly) stood at $270.0 million in 2020, then soared by 177.96% to $750.4 million in 2021, then dropped by 14.32% to $643.0 million in 2022, then fell by 1.56% to $633.0 million in 2023, then rose by 5.06% to $665.0 million in 2024.